Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement. VTU Technology, currently offering a very broad and versatile technology platform available for Pichia pastoris protein production, will be responsible for carrying out the joint development program in VTU´s facilities in close collaboration between researchers from both companies. Boehringer Ingelheim has decided to prolong their ongoing technology agreement with VTU to further strengthen Pichia’s position as a highly attractive and competitive host for the production of biopharmaceuticals.

“The ongoing commitment of Boehringer Ingelheim in our technology collaboration underlines the skills and capabilities of our great team. We are very much looking forward to new exciting developments in this fruitful collaboration”, said Dr. Thomas Purkarthofer, Head of Business Development at VTU Technology.

“We are excited about the continuation of our successful collaboration with VTU Technology. Together we established Pichia pastoris as innovative platform for the manufacture of biopharmaceuticals,” said Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim. “With the renewal of our collaboration we will further expand our technological lead for Boehringer Ingelheim’s own development projects as well as for Boehringer Ingelheim BioXcellenceTM customers globally.”